October 5, 2022 – RedDress, a privately held U.S. and Israel-based global medical device company that features a suite of advanced wound care products, announced it has received a contract from Vizient. The contract was awarded based on the recommendation of RedDress’s wound care products by hospital experts who serve on one of Vizient’s member-led councils, and it signifies to Vizient members unique qualities that potentially bring improvement to the health care industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient member-led councils identify technologies that have the potential to enhance clinical care, patient safety, health care worker safety, or improve business operations of health care organizations.
The agreement gives increased access of RedDress’ suite of ActiGraft products to Vizient’s member base, which is comprised of academic medical centers, community hospitals, integrated health delivery networks and non-acute health care providers. Available solutions include:
- ActiGraft® System: The original autologous, point of care management system which enables health providers to produce – in real time – in vitro blood clots from a patient’s whole blood
- ActiGraft+® System: The updated version of our flagship product which features a proprietary calcium gluconate powder to create the whole blood clot.
“After attending the Innovation Technology Exchange last September, receiving this contract is further acknowledgment of ActiGraft’s potential to become the new standard of care when treating chronic wounds, such as diabetic foot ulcers and pressure injuries. We are looking forward to continuing to improve patient outcomes through this agreement,” said Russell Lalli, President of RedDress.